| human | Q5 |
| P496 | ORCID iD | 0000-0002-5178-5827 |
| P11725 | PubliCatt author ID | 22564 |
| P3829 | Publons author ID | 1206704 |
| P1053 | ResearcherID | J-3650-2018 |
| P1153 | Scopus author ID | 7006192748 |
| P735 | given name | Valerio | Q17524272 |
| Valerio | Q17524272 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q115294583 | A Novel Morphological Parameter Predicting Fibrotic Evolution in Myeloproliferative Neoplasms: New Evidence and Molecular Insights |
| Q100558665 | A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis |
| Q38041793 | Abdominal thromboses of splanchnic, renal and ovarian veins. |
| Q83071318 | Absence of the JAK2 exon 12 mutations in patients with splanchnic venous thrombosis and without overt myeloproliferative neoplasms |
| Q73916270 | Acquired and inherited risk factors for splanchnic venous thrombosis |
| Q63247711 | Additional genetic risk factors for venous thromboembolism in carriers of the factor V Leiden mutation. |
| Q92509180 | Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper |
| Q45865988 | Alpha(2)-macroglobulin levels are high in adult patients with congenital antithrombin deficiency |
| Q45872843 | Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers. |
| Q35539424 | Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis of observational studies |
| Q71039029 | Antithrombin III and factor Xa inhibitor in atherosclerosis |
| Q43716343 | Antithrombotic prophylaxis during pregnancy in women with deficiency of natural anticoagulants. |
| Q38137750 | Are MPNs vascular diseases? |
| Q85653417 | Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patients |
| Q92206129 | Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study |
| Q44781119 | Association of Graves' disease and prekallikrein congenital deficiency in a patient belonging to the first CRM+ prekallikrein-deficient Italian family |
| Q28082873 | Associations of antiphospholipid antibodies with splanchnic vein thrombosis: a systematic review with meta-analysis |
| Q35162504 | Associations of coagulation factor V Leiden and prothrombin G20210A mutations with Budd-Chiari syndrome and portal vein thrombosis: a systematic review and meta-analysis |
| Q51129997 | Autoimmune hemolytic anemia with gel-based immunohematology tests: neural network analysis. |
| Q35886257 | Bisphosphonate therapy in multiple myeloma in preventing vertebral collapses: preliminary report. |
| Q56981141 | Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma |
| Q98726025 | COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey |
| Q44793541 | Cardiovascular events and intensity of treatment in polycythemia vera |
| Q35640769 | Causes of adult splanchnic vein thrombosis in the mediterranean area. |
| Q43922582 | Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European Leukemia Net study |
| Q61758699 | Cerebral venous thrombosis and myeloproliferative neoplasms: Results from two large databases |
| Q84373351 | Cerebral venous thrombosis and the risk of pregnancy-related recurrent venous thromboembolism |
| Q60171394 | Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia |
| Q43621401 | Clonal hemopoiesis and risk of thrombosis in young female patients with essential thrombocythemia. |
| Q39210015 | Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria phenotype in patients with splanchnic vein thrombosis. |
| Q39542698 | Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). |
| Q33388109 | Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia |
| Q59335352 | Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera |
| Q80710270 | Early postoperative obstructive prosthetic mitral valve thrombosis in a patient double heterozygous for factor V Leiden and prothrombin G20210A mutation |
| Q45859145 | Effect of prothrombin 19911 A>G polymorphism on the risk of cerebral sinus-venous thrombosis |
| Q92762642 | Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis |
| Q44144913 | Efficacy of lenalidomide plus dexamethasone for POEMS syndrome relapsed after autologous peripheral stem-cell transplantation. |
| Q54681025 | Evaluation of the prevalence of severe hyperhomocysteinemia in adult patients with thrombosis who underwent screening for thrombophilia. |
| Q38041794 | Extra-abdominal venous thromboses at unusual sites. |
| Q73229748 | Failure of fibrinolytic endoventricular treatment to prevent neonatal post-haemorrhagic hydrocephalus. A case-control trial |
| Q45871743 | Five novel point mutations: two causing haemophilia B and three causing factor X deficiency |
| Q33422323 | Fondaparinux in pregnancy: Could it be a safe option? A review of the literature |
| Q101220969 | Full Donor Chimerism After Allogeneic Hematopoietic Stem Cells Transplant For Myelofibrosis: The Role Of The Conditioning Regimen |
| Q57070978 | Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project |
| Q50477112 | Haemoglobin levels in autoimmune haemolytic anaemias at diagnosis: relationship with immunoproteins on red blood cells. |
| Q51186463 | Haemostatic alterations induced by treatment with asparaginases and clinical consequences. |
| Q68244700 | Hepatocarcinoma in cirrhosis. Is antithrombin III a neoplastic marker? |
| Q104795200 | High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib |
| Q79839975 | High prevalence of the JAK2 V617F mutation in patients with extrahepatic portal vein thrombosis |
| Q97069845 | How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy-a GIMEMA MPN WP survey |
| Q58695607 | Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases |
| Q40291287 | Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN. |
| Q38174710 | Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: a consensus-based SIE, SIES, GITMO position paper |
| Q35950753 | IgD multiple myeloma a descriptive report of 17 cases: survival and response to therapy |
| Q35636700 | Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study |
| Q90541890 | Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group |
| Q39270841 | Impact of radiotherapy on pain relief and recalcification in plasma cell neoplasms: long-term experience. |
| Q84743882 | In families with inherited thrombophilia the risk of venous thromboembolism is dependent on the clinical phenotype of the proband |
| Q91735868 | In vitro effect of eltrombopag alone and in combination with azacitidine on megakaryopoiesis in patients with myelodysplastic syndrome |
| Q79690448 | Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders |
| Q43757657 | Increased prevalence of the G20210A prothrombin gene variant in acute coronary syndromes without metabolic or acquired risk factors or with limited extent of disease. |
| Q60916121 | Indications and use of therapeutic phlebotomy in polycythemia vera: which role for erythrocytapheresis? |
| Q45855734 | Influence of proband's characteristics on the risk for venous thromboembolism in relatives with factor V Leiden or prothrombin G20210A polymorphisms. |
| Q37175624 | Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia. |
| Q38178063 | Inherited risk factors for venous thromboembolism |
| Q83118521 | Inherited thrombophilia: treatment during pregnancy |
| Q92622295 | Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative |
| Q84146227 | JAK2 V617F mutational frequency in essential thrombocythemia associated with splanchnic or cerebral vein thrombosis |
| Q28210331 | Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera |
| Q40744463 | Long-term Clinical Outcomes of Splanchnic Vein Thrombosis: Results of an International Registry. |
| Q33387332 | Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study |
| Q68424746 | Mesenteric vein thrombosis in protein S congenital deficiency |
| Q35158686 | Methylenetetrahydrofolate reductase C677T gene mutation and hyperhomocysteinemia in Budd-Chiari syndrome and portal vein thrombosis: A systematic review and meta-analysis of observational studies. |
| Q73651570 | Molecular and clinical follow-up after stem cell transplantation for multiple myeloma |
| Q44059578 | Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases. |
| Q44024123 | Myeloid sarcoma with megakaryoblastic differentiation mimicking a sellar tumor. |
| Q71112355 | Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry |
| Q35867315 | Novel antithrombotic agents: indirect synthetic inhibitors of factor Xa and direct thrombin inhibitors. Evidences from clinical studies. |
| Q57573580 | Obstetric complications and pregnancy-related venous thromboembolism: The effect of low-molecular-weight heparin on their prevention in carriers of factor V Leiden or prothrombin G20210A mutation |
| Q46985882 | Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial |
| Q28207385 | Overexpression of the polycythemia rubra vera-1 gene in essential thrombocythemia |
| Q118144168 | Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios |
| Q44117506 | Platelet activation and inhibition in polycythemia vera and essential thrombocythemia |
| Q44409078 | Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey |
| Q41754449 | Prevalence of factor V Leiden and the G20210A prothrombin-gene mutation in inflammatory bowel disease. |
| Q34502105 | Prevalence of inherited antithrombin, protein C, and protein S deficiencies in portal vein system thrombosis and Budd-Chiari syndrome: a systematic review and meta-analysis of observational studies. |
| Q78167246 | Prevalence of mild hyperhomocysteinaemia and association with thrombophilic genotypes (factor V Leiden and prothrombin G20210A) in Italian patients with venous thromboembolic disease |
| Q54776413 | Prevalence of the JAK2 V617F mutation in patients with unprovoked venous thromboembolism of common sites and without overt myeloproliferative neoplasms. |
| Q84565134 | Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form |
| Q36685162 | Prophylaxis and treatment of venous thromboembolism in individuals with inherited thrombophilia. |
| Q83278454 | Protein Z g-42a variant and the risk of pregnancy-related venous thromboembolism in a cohort of Italian patients |
| Q63247677 | Rare thromboses of cerebral, splanchnic and upper-extremity veins |
| Q48431192 | Recombinant plasminogen activator therapy for cerebral vein thrombosis in a child carrier of prothrombin gene mutation |
| Q63247666 | Recommendations for prophylaxis of pregnancy-related venous thromboembolism in carriers of inherited thrombophilia. Comment on the 2012 ACCP guidelines |
| Q61050105 | Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments |
| Q91174026 | Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin |
| Q45863926 | Reply: Interaction between inherited thrombophilia and HIV infection: fact or fancy? |
| Q81235620 | Report of a novel kindred with antithrombin heparin-binding site variant (47 Arg to His): demand for an automated progressive antithrombin assay to detect molecular variants with low thrombotic risk |
| Q44878802 | Risk factor and etiology analysis of ischemic stroke in young adult patients |
| Q37604068 | Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls |
| Q48151694 | Role of flow-cytometric immunophenotyping in prediction of BCR/ABL1 gene rearrangement in adult B-cell acute lymphoblastic leukemia. |
| Q42829579 | Safety of granulocyte-colony-stimulating factor in acute myocardial infarction (the Rigenera study). |
| Q37578073 | Screening for thrombophilia and antithrombotic prophylaxis in pregnancy: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). |
| Q92382938 | Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study |
| Q91801892 | Second cancers in MPN: Survival analysis from an international study |
| Q91265956 | Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases |
| Q37763593 | Splanchnic vein thrombosis: clinical presentation, risk factors and treatment. |
| Q57573574 | Structural analysis of protein Z gene variants in patients with foetal losses |
| Q58592851 | Targeting myeloid cells to prevent recurrent stroke in general population: the lesson of hydroxyurea in myeloproliferative neoplasms |
| Q51225186 | Testing for inherited thrombophilia and consequences for antithrombotic prophylaxis in patients with venous thromboembolism and their relatives. A review of the Guidelines from Scientific Societies and Working Groups. |
| Q74263385 | The C807T/G873A polymorphism in the platelet glycoprotein Ia gene and the risk of acute coronary syndrome in the Italian population |
| Q33303765 | The G20210A prothrombin variant and the risk of venous thromboembolism or fetal loss in pregnant women: a family study. |
| Q81389978 | The JAK2 V617F mutation in patients with cerebral venous thrombosis: a rebuttal |
| Q63247710 | The Risk of Recurrent Deep Venous Thrombosis among Heterozygous Carriers of Both Factor V Leiden and the G20210A Prothrombin Mutation |
| Q43281710 | The interaction between small intestinal bacterial overgrowth and warfarin treatment |
| Q92337657 | The prognostic impact of monoclonal immune globulin and free light chain secretion in diffuse large B cell lymphoma (DLBCL) |
| Q45874308 | The risk of first venous thromboembolism during pregnancy and puerperium in double heterozygotes for factor V Leiden and prothrombin G20210A. |
| Q63247703 | The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation |
| Q81389924 | The risk of symptomatic pulmonary embolism due to proximal deep venous thrombosis differs in patients with different types of inherited thrombophilia |
| Q81064713 | The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment |
| Q45874156 | The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both |
| Q53582176 | Thrombopoietin receptor agonists significantly increase the risk of portal vein thrombosis in liver diseases: Meta-analysis of RCTs. |
| Q33415996 | Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors. |
| Q89882063 | Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis |
| Q33413686 | Venous thromboembolism in multiple myeloma |
| Q86912642 | Venous thromboembolism in patients with liver diseases |
| Q47260924 | Vitamin D deficiency and supplementation in patients with aggressive B-cell lymphomas treated with immunochemotherapy. |
Search more.